First-Line Fulvestrant/Palbociclib vs Letrozole/Palbociclib for Endocrine-Sensitive, HR-Positive, HER2-Negative Advanced Breast Cancer – The ASCO Post

By Matthew Stenger Posted: 10/19/2021 12:43:00 PM Last Updated: 10/19/2021 12:54:27 PM In the phase II PARSIFAL trial reported in JAMA Oncology, Antonio Llombart-Cussac, MD, and colleagues found that the combination of fulvestrant plus palbociclib did not improve…

Read the full article here

Related Articles